Advertisement
Research Article

A Double-Blind, Placebo-Controlled, Randomized, Clinical Trial of the TLR-3 Agonist Rintatolimod in Severe Cases of Chronic Fatigue Syndrome

  • David R. Strayer mail,

    david.strayer@hemispherx.net (DRS); bill.mitchell@vanderbilt.edu (WMM)

    Affiliation: Hemispherx Biopharma, Inc., Philadelphia, Pennsylvania, United States of America

    X
  • William A. Carter,

    Affiliation: Hemispherx Biopharma, Inc., Philadelphia, Pennsylvania, United States of America

    X
  • Bruce C. Stouch,

    Affiliation: BCS Consulting, Philadelphia, Pennsylvania, United States of America

    X
  • Staci R. Stevens,

    Affiliation: University of the Pacific, Stockton, California, United States of America

    X
  • Lucinda Bateman,

    Affiliation: Fatigue Consultation Clinic, Salt Lake City, Utah, United States of America

    X
  • Paul J. Cimoch,

    Affiliation: Center for Special Immunology, Fountain Valley, California, United States of America

    X
  • Charles W. Lapp,

    Affiliation: Hunter-Hopkins Center, Charlotte, North Carolina, United States of America

    X
  • Daniel L. Peterson,

    Affiliation: Sierra Internal Medicine Associates, Incline Village, Nevada, United States of America

    X
  • the Chronic Fatigue Syndrome AMP-516 Study Group,

    For a list of the members of Chronic Fatigue Syndrome AMP-516 Clinical Study Group please see Table S2.

    X
  • William M. Mitchell mail

    david.strayer@hemispherx.net (DRS); bill.mitchell@vanderbilt.edu (WMM)

    Affiliation: Vanderbilt University School of Medicine, Nashville, Tennessee, United States of America

    X
  • Published: March 14, 2012
  • DOI: 10.1371/journal.pone.0031334

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.